Navigation Links
Essentialis Secures Foundation for Prader-Willi Research Grant to Help Advance DCCR in the Treatment of Prader-Willi Syndrome
Date:7/23/2014

CARLSBAD, Calif., July 23, 2014 /PRNewswire/ -- Essentialis announced today the receipt of a grant from the Foundation for Prader-Willi Research (FPWR) to support clinical study PC025, which is designed to evaluate the safety and efficacy of diazoxide choline controlled release tablets (DCCR) in obese Prader-Willi syndrome patients. The clinical study is being conducted at the University of California, Irvine under the direction of Dr. Virginia Kimonis.

"We have found that the support of FPWR extends well beyond the grant. They have actively promoted this clinical study through their extensive connections in the Prader-Willi community, increasing the pace of recruitment, and they shared the input of experts, improving the design of the clinical study," said Dr. Neil M. Cowen, President and Chief Scientific Officer of Essentialis. 

"FPWR is looking forward to the results of clinical study PC025 and to the further development of DCCR in the treatment of Prader-Willi syndrome where it has the potential to address a significant unmet medical need," said Dr. Theresa V. Strong, chair of the FPWR Scientific Advisory Board. "This is the first time FPWR has provided funding to a company developing a drug to treat PWS."

About DCCR DCCR is a proprietary crystalline salt of diazoxide formulated as a controlled-release, once-a-day tablet. It is in development for the treatment of Prader-Willi syndrome and hypothalamic obesity. DCCR is covered by multiple issued US and granted EU and Japanese patents, which provide composition of matter protection until 2028. Essentialis is globally prosecuting claims to the use of pharmaceutical formulations of KATP channel activators including diazoxide and DCCR in the treatment of Prader-Willi syndrome. Essentialis has evaluated DCCR in more than 200 subjects in multiple double-blind, placebo-controlled studies. More information about clinical study PC025 can be found at www.clinicaltrials.gov using identifier NCT02034071.

About FPWR The Foundation for Prader-Willi Research was established in 2003 by a small group of parents who saw the need to foster research that would help their children with Prader-Willi syndrome lead more healthy and fulfilling lives. Today, FPWR is composed of hundreds of parents, family members, researchers, and others who are interested in addressing the many issues related to PWS, including childhood obesity, developmental delay, psychiatric disorders, and autism spectrum disorders.  The mission of FPWR is to eliminate the challenges of Prader-Willi syndrome through the advancement of research. For more information visit http://www.fpwr.org/

About Essentialis, Inc. Essentialis is a Carlsbad-based, orphan drug focused, pharmaceutical company focused on the development of breakthrough medicines targeted to the ATP-sensitive potassium channel, a metabolically regulated membrane protein whose modulation has the potential to treat and prevent a wide range of metabolic, CNS and cardiovascular diseases.

For more information visit http://essentialistherapeutics.com/.


'/>"/>
SOURCE Essentialis, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. DICOM Grid Secures $6 Million to Meet Growing Demand for Digital Medical Imaging in the Cloud
2. Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis
3. Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College
4. Liberty Design Secures GSA Award, to Supply Federal Agencies
5. Sanomedics Secures $5 Million Revolving Credit Facility With TCA Global Credit Master Fund, LP To Fund Growth And Future Acquisitions
6. Halozyme Secures Additional $20 Million Term Loan
7. AcelRx Secures $40 Million Credit Facility with Hercules Technology Growth Capital
8. Total Artificial Heart Manufacturer SynCardia Secures $14M in Growth Financing
9. Zafgen Secures $45 Million in Series E Financing
10. Collaborative Medical Technology Corporation Secures Investments from Two Prominent Medical Specialists
11. Calithera Biosciences Secures $35 Million in Series D Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... 2016 /PRNewswire/ - InMed Pharmaceuticals, Inc. ("InMed") (CSE: ... R&D program in the use of cannabinoids for ... In June, 2015 InMed initiated its COPD program ... targets and potential active compounds that can be ... in vitro assays using human lung fibroblasts (HFL-1 ...
(Date:12/5/2016)...  Balloon catheter is an innovative medical device that ... femoral artery in the leg or sometimes into the ... vessels. These products are generally used to prevent blood ... lipid substances in the blood vessel. In terms of ... expand at a CAGR of 3.8% during the forecast ...
(Date:12/5/2016)... , Dec. 5, 2016 Spain Glaucoma ... GlobalData,s new report, "Spain Glaucoma Surgery Devices Market Outlook ... Glaucoma Surgery Devices market. The report provides value, in ... prices (USD) within market segements - Canaloplasty Micro Catheters ... company shares and distribution shares data for each of ...
Breaking Medicine Technology:
(Date:12/6/2016)... Albuquerque, NM (PRWEB) , ... December 06, 2016 ... ... awarded JumpStart Autism Center with an Award of Distinction, recognizing the organization as ... needs providers that excel in the areas of clinical quality, staff satisfaction and ...
(Date:12/6/2016)... ... December 06, 2016 , ... Experimentation involving human stem cells ... due to its potential for revolutionizing human disease treatment. There are multiple HSC ... stem cells (hiPSCs). , Both platforms have distinct advantages and disadvantages, but ...
(Date:12/6/2016)... , ... December 06, 2016 , ... ... one-stop portal for all the knowledge resources, including white papers, guides, handbooks, case ... more. , To access more than 9,000 documents, webinars and videos available ...
(Date:12/6/2016)... , ... December 06, 2016 , ... 'Tis the season ... daily routines. That means it's also the season when eating healthy, staying active, and ... diabetes) on schedule is harder to do. , "Shopping trips, parties and family ...
(Date:12/6/2016)... ... 06, 2016 , ... Specialty Technical Publishers (STP) and Specialty ... Consortium (IAPC) EHS audit protocol for Great Britain . Leading companies around ... EHS regulatory obligations and rapidly collect, share, archive, and export audit findings in ...
Breaking Medicine News(10 mins):